Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| CYTK | CLUSTER | neutral | 3/10 | CEO Robert Blum and EVP Andrew Callos each exercised and immediately sold vested stock options on the same day, totaling | Aug 31, 2026 |
| ETON | CLUSTER | neutral | 4/10 | Two Eton Pharmaceuticals insiders (a director and the Chief Business Officer) sold a combined $2.44M in shares over a on | Aug 31, 2026 |
| CERO | 8-K | bearish | 7/10 | CERO Therapeutics completed a secured financing with SRX Global, consolidating $5.67M of prior unsecured debt into a new | Aug 31, 2026 |
| PMVP | PRESS-RELEASE | bearish | 6/10 | PMV Pharma commences an underwritten public offering of common stock, pre-funded warrants, and warrants. The offering si | Aug 31, 2026 |
| PMVP | PRESS-RELEASE | bullish | 8/10 | PMV Pharma announced updated interim Phase 2 data for rezatapopt in TP53 Y220C-mutant platinum-resistant/refractory ovar | Aug 31, 2026 |
| BBIO | 8-K | neutral | 4/10 | BridgeBio announced a voluntary agreement with the U.S. government to lower drug costs and expand Medicaid access to its | Aug 31, 2026 |
| NYMXF | 6-K | neutral | 2/10 | Nymox Pharmaceutical Corp filed a 6-K reporting the results of a special shareholder meeting held on August 28, 2026, wh | Aug 31, 2026 |
| BLRX | 424B5 | bearish | 7/10 | BioLineRx is raising approximately $3.3 million in net proceeds through a registered direct offering of 480,696 ADSs and | Aug 31, 2026 |
| KZIA | 424B5 | bearish | 6/10 | Kazia Therapeutics is raising approximately $37M in net proceeds through an underwritten public offering of 2,276,800 AD | Aug 31, 2026 |
| KZIA | 6-K | bearish | 6/10 | Kazia Therapeutics filed the underwriting agreement for its previously announced public offering of 2,276,800 ADSs, pre- | Aug 31, 2026 |
| ATHE | 6-K | neutral | 3/10 | Alterity Therapeutics entered into an underwriting agreement with MST Financial Services to underwrite the exercise of u | Aug 31, 2026 |
| HCM | 6-K | bullish | 7/10 | HUTCHMED announces positive Phase III SANOVO trial results showing ORPATHYS (savolitinib) plus TAGRISSO (osimertinib) si | Aug 31, 2026 |
| BMRN | 8-K | bullish | 6/10 | BioMarin entered a binding term sheet with Ascendis Pharma to settle all global patent litigation. Ascendis will pay Bio | Aug 31, 2026 |
| RDHL | 6-K | bullish | 7/10 | RedHill Biopharma divests its 70% stake in Talicia to Apotex for $18M upfront plus up to $35M in milestones, directly ad | Aug 31, 2026 |
| BLRX | 6-K | bearish | 6/10 | BioLineRx reported Q2 2026 results with net loss widening to $4.3M (vs $3.9M a year ago) and H1 loss of $6.9M vs income | Aug 31, 2026 |
| KZIA | 6-K | neutral | 2/10 | Kazia Therapeutics filed a routine 6-K announcing the launch of a new website (www.kaziatx.com) and an updated URL. The | Aug 31, 2026 |
| ALVO | 6-K | bullish | 7/10 | Alvotech announced FDA acceptance for review of its BLA for AVT80, a proposed interchangeable biosimilar to Entyvio (ved | Aug 31, 2026 |
| BLRX | 6-K | bearish | 6/10 | BioLineRx filed a securities purchase agreement for a registered direct offering of approximately $3,750,000, consisting | Aug 31, 2026 |
| KPTI | 8-K | bullish | 6/10 | Karyopharm announced submission of an sNDA to the FDA seeking Accelerated Approval for XPOVIO (selinexor) in combination | Aug 31, 2026 |
| AVXL | DEFA14A | neutral | 6/10 | Anavex Life Sciences management mailed a stockholder letter on August 31, 2026, soliciting support for its board slate a | Aug 31, 2026 |
| CVKD | 8-K | bullish | 6/10 | Cadrenal Therapeutics announced positive feedback from an FDA Type D meeting for its Phase 3 registrational study of CAD | Aug 31, 2026 |
| CYTK | PRESS-RELEASE | bullish | 7/10 | Cytokinetics presented positive additional Phase 3 results at ESC 2026 showing aficamten (MYQORZO) improves cardiac stru | Aug 29, 2026 |
| TENX | PRESS-RELEASE | mixed | 7/10 | Tenax Therapeutics presented additional Phase 3 LEVEL trial data for TNX-103 (oral levosimendan) in PH-HFpEF at ESC 2026 | Aug 29, 2026 |
| RLAY | CLUSTER | bearish | 6/10 | Two insiders at Relay Therapeutics sold a combined $116.49M in shares over a 7-day window. The overwhelming majority ($1 | Aug 29, 2026 |
| MEDP | CLUSTER | neutral | 4/10 | A significant insider selling cluster at Medpace (MEDP) totaling $14.45M over a 7-day window, led by CEO August Troendle | Aug 29, 2026 |
| OMER | CLUSTER | neutral | 5/10 | Three OMER insiders, including two directors and the VP of Finance, sold a total of ~$387K in open-market shares over a | Aug 29, 2026 |
| CORT | CLUSTER | neutral | 2/10 | Two Corcept Therapeutics insiders, Director Kimberly Park and executive Sean Maduck, sold a combined $4.01M in open-mark | Aug 29, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | CEO Martine Rothblatt executed a large derivative exercise of 9,500 shares at $135.42, then immediately sold the resulti | Aug 29, 2026 |
| PGEN | CLUSTER | neutral | 3/10 | A mixed insider cluster at Precigen shows a director selling $1.38M in open-market shares and the CCO selling $594K post | Aug 28, 2026 |
| MNPR | CLUSTER | neutral | 2/10 | Three Monopar insiders (two directors and one insider) sold a total of ~$257K in open-market sales over a two-day window | Aug 28, 2026 |